LSD treatment affects working memory-related brain function in patients with major depressive disorder
Abstract
Classic psychedelics, including lysergic acid diethylamide (LSD), are currently under investigation for the treatment of major depressive disorder (MDD). Cognitive dysfunction is common in MDD, but effects of psychedelic treatment on cognitive brain function, measured by magnetic resonance imaging, are sparsely reported. The present study investigated effects of LSD treatment on working memory-related brain function in patients with MDD. In a randomized, double-blind, parallel-group trial, 43 patients with MDD received either two low-dose (25 µg) or two high-dose (100 and 200 µg) oral LSD treatments 4 weeks apart. Functional magnetic resonance imaging during an n-back working memory task was conducted before and approximately 1 week after the second treatment. The treatment × time interaction effect on working memory-related brain responses (2-back and 1-back vs . 0-back) was assessed using linear mixed effects models. We also explored associations between brain responses and depression severity, task performance, and subjective psychedelic experiences. Compared with low-dose treatment, high-dose LSD treatment significantly increased working memory-related brain responses ( p = 0.007) within task-activated regions, including the dorsolateral prefrontal cortex, parietal cortex, insula, striatum, and thalamus. Working memory-related brain responses correlated with task performance and subjective perceptual changes but not treatment response. Our observations provide the first evidence that LSD treatment in patients with MDD affects cognitive brain function. Contrary to our hypothesis, high-dose LSD significantly increased brain responses. These responses positively correlated with task performance, suggesting a potential LSD-induced boost in neural function. The absence of an association with depressive symptoms indicates that task-related brain activity may underlie different mechanisms than changes in mood. Trial registration: Clinicaltrials.gov Identifier: NCT03866252.
Related
- Association of neurotransmitter-based polygenic scores with antidepressant treatment outcomes in patients with major depressive disorder
- Sex differences in the association between body mass index and recent suicide attempts in treatment-naïve young adults with major depressive disorder
- Neuroplasticity-Based Treatment Prioritization in Major Depressive Disorder: A Two-Cohort Study
- The acute phase inflammatory response as a key determinant of reduced lipid-associated antioxidant defenses in Chinese patients with major depressive disorder
- Association of Cognitive Function With Event-Related Potentials and Immune Inflammation in Adolescents With Major Depressive Disorder.
BibTeX
@article{holze2026treatment,
title = {{LSD treatment affects working memory-related brain function in patients with major depressive disorder}},
author = {Friederike Holze and Kristian Larsen and Brice Ozenne and Gitte M. Knudsen and Anna M. Becker and Mihai Avram and Stefan Borgwardt and Matthias E. Liechti and Felix Müller and Patrick M. Fisher},
journal = {Translational Psychiatry},
year = {2026},
month = oct,
doi = {10.1038/s41398-026-04522-4},
url = {https://www.nature.com/articles/s41398-026-04522-4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - LSD treatment affects working memory-related brain function in patients with major depressive disorder
AU - Friederike Holze
AU - Kristian Larsen
AU - Brice Ozenne
AU - Gitte M. Knudsen
AU - Anna M. Becker
AU - Mihai Avram
AU - Stefan Borgwardt
AU - Matthias E. Liechti
AU - Felix Müller
AU - Patrick M. Fisher
PY - 2026
DA - 2026/10/08
JO - Translational Psychiatry
DO - 10.1038/s41398-026-04522-4
UR - https://www.nature.com/articles/s41398-026-04522-4
AB - Classic psychedelics, including lysergic acid diethylamide (LSD), are currently under investigation for the treatment of major depressive disorder (MDD). Cognitive dysfunction is common in MDD, but effects of psychedelic treatment on cognitive brain function, measured by magnetic resonance imaging, are sparsely reported. The present study investigated effects of LSD treatment on working memory-related brain function in patients with MDD. In a randomized, double-blind, parallel-group trial, 43 patients with MDD received either two low-dose (25 µg) or two high-dose (100 and 200 µg) oral LSD treatments 4 weeks apart. Functional magnetic resonance imaging during an n-back working memory task was conducted before and approximately 1 week after the second treatment. The treatment × time interaction effect on working memory-related brain responses (2-back and 1-back vs . 0-back) was assessed using linear mixed effects models. We also explored associations between brain responses and depression severity, task performance, and subjective psychedelic experiences. Compared with low-dose treatment, high-dose LSD treatment significantly increased working memory-related brain responses ( p = 0.007) within task-activated regions, including the dorsolateral prefrontal cortex, parietal cortex, insula, striatum, and thalamus. Working memory-related brain responses correlated with task performance and subjective perceptual changes but not treatment response. Our observations provide the first evidence that LSD treatment in patients with MDD affects cognitive brain function. Contrary to our hypothesis, high-dose LSD significantly increased brain responses. These responses positively correlated with task performance, suggesting a potential LSD-induced boost in neural function. The absence of an association with depressive symptoms indicates that task-related brain activity may underlie different mechanisms than changes in mood. Trial registration: Clinicaltrials.gov Identifier: NCT03866252.
SN - 2158-3188
ER -